GNOSPV-01 is under clinical development by Geneos Therapeutics and currently in Phase I for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase I drugs for Hormone-Sensitive Prostate Cancer have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GNOSPV-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GNOSPV-01 overview

GNOSPV-01 is under investigation for the prevention of recurrent brain tumor, metastatic hormone-sensitive prostate cancer, triple negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, adenocarcinoma of pancreatic cancer and follicular lymphoma. Personalized peptide vaccination identifies the specific peptides that mark the tumor as dangerous and reintroduce them in increased concentration to the immune system via vaccination. It is administered through subcutaneous and intramuscular route. The vaccine candidate was also under development for renal cell carcinoma.

Geneos Therapeutics overview

Geneos Therapeutics, is a biopharmaceutical company that develops neoantigen targeting cancer immunotherapies. The company is headquartered in United States.

For a complete picture of GNOSPV-01’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.